Related Experiment Videos
Monoclonal antibody directed to human T-cell malignancy antigen
M Minegishi1, S Tsuchiya, N Minegishi
1Department of Pediatrics, Tohoku University, Sendai, Japan.
Leukemia Research
|January 1, 1989
Summary
Researchers developed a new monoclonal antibody, B2D, highly specific for T-cell acute lymphoblastic leukemia (T-ALL). This antibody shows promise for T-ALL subclassification and potential therapeutic applications in specific T-ALL cases.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Acute lymphoblastic leukemia (ALL) is a significant hematologic malignancy.
- T-cell ALL (T-ALL) is a subtype requiring specific diagnostic markers.
- Development of targeted therapies necessitates identification of specific cell surface antigens.
Purpose of the Study:
- To produce and characterize a novel murine monoclonal antibody (B2D).
- To evaluate the specificity of B2D against T-ALL cell lines and patient samples.
- To investigate the potential diagnostic and therapeutic utility of B2D in T-ALL.
Main Methods:
- Production of a murine monoclonal antibody (B2D) against the THP-6 pre-T ALL cell line.
- Immunological assays including antibody reactivity testing against various cell types (T-ALL lines, patient leukemic cells, normal lymphocytes, other leukemia cells).
- Immunoprecipitation to determine the molecular weight of the target antigen.
Main Results:
- The B2D antibody demonstrated high reactivity with cultured T-ALL cell lines and primary T-ALL/lymphoma patient cells.
- B2D showed no reactivity with normal hematopoietic cells, thymocytes, or non-T cell leukemias.
- The target antigen immunoprecipitated by B2D has a molecular weight of 50-55 kD, indicating high specificity for T-ALL.
Conclusions:
- Monoclonal antibody B2D is highly specific for T-cell malignancies, particularly T-ALL.
- B2D identifies a unique human leukemia antigen expressed on the surface of T-ALL cells.
- B2D holds potential for T-ALL subclassification and targeted therapeutic strategies.